The scientific article entitled "Bioconjugation of photon-upconversion nanoparticles for cancer biomarker detection and imaging" is now published in the scientific journal Nature Protocols. Read the article here.
Dr. Matthias Mickert, Senior Chemical Engineer at Lumito, was part of the Gorris group at the University of Regensburg, which recently moved to Masaryk University in Brno. The article summarizes the group's research and describes methods for the synthesis and conjugation of UCNPs (upconversion nanoparticles) previously established by the group.
Nature Protocols is a well-known scientific journal with a good reputation and a high two-year impact factor of 13.49. The main objective of the journal is to publish the best protocols from leading experts in chemistry, biology, and clinical science.
For further information, please contact:
Lumito's CEO, Mattias Lundin
phone: +46 76-868 45 09
Also, visit our website.
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. www.lumito.se.
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 (8) 5030 1550 and email, firstname.lastname@example.org.